ProMIS Neurosciences Stock
ProMIS Neurosciences, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- CEO
- Neil K. Warma
- Employees
- 11
- Market cap
- $73 M
- IPO
- 10/01/2007
ProMIS Neurosciences, Inc. is a Canadian biotechnology firm dedicated to creating targeted therapeutic solutions for debilitating neurodegenerative conditions such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company leverages a unique computational discovery…
ProMIS Neurosciences stock: price history
1D
-6.3%
1W
-15.2%
1M
-36.7%
6M
-29.3%
YTD
+19.3%
1Y
-30.2%
2Y
-68.7%
5Y
-96.4%
10Y
-94.6%
Next earnings date
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
~0% stronger price swings than usual
Ask the agents about ProMIS Neurosciences
Analyst assessment of ProMIS Neurosciences
PRICE TARGET LOW
US$29.00
CONSENSUS
US$31.00
MEDIAN
US$31.00
PRICE TARGET HIGH
US$33.00
0
STRONG BUY
3
BUY
0
HOLD
0
SELL
0
STRONG SELL
3
TOTAL · Buy
As of: 14/08/2026
ProMIS Neurosciences stock metrics
P/E
-0.48
P/B
1.51
EV/EBITDA
-0.46
RETURN ON EQUITY
-23.7%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
78.4%
FLOAT SHARES
7,031,120
AVG. DAILY VOLUME (30D)
36,942
Insider transactions (SEC)
Kaplan Johanne
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about ProMIS Neurosciences stock
What does ProMIS Neurosciences do?
ProMIS Neurosciences, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in Canada.
The CEO is Neil K. Warma, the company employs around 11 people.
The IPO was on 10/01/2007; the stock trades on NASDAQ under the ticker PMN.
What do analysts say about ProMIS Neurosciences stock?
3 analysts rate the stock, the consensus is Buy (as of 14/08/2026).
The average price target is US$31.00, ranging from US$29.00 to US$33.00, with a median of US$31.00.
This is an external assessment, not a statement by Market Jury.
When does ProMIS Neurosciences report next?
The next earnings date is 11/11/2026.
Around past earnings, price swings were roughly 0% stronger than usual.
Does ProMIS Neurosciences pay a dividend?
No, ProMIS Neurosciences currently does not pay a dividend.
Which stocks are comparable to ProMIS Neurosciences?
Comparable stocks include AbCellera Biologics, Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines and Incyte.
How can I get ProMIS Neurosciences stock analyzed?
Clicking "Analyze stock" lets five strategies assess ProMIS Neurosciences against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.